As I see it, owning shares in both RVX and ZHCLF is an ideal combination. 

If Zenith Epigenetics is sold "ZHCLF" shares will be at least worth the book value of Zenith Capital Corp (ZCC) as the funds from the sale will fall into its hands.

As intended by ZCC management, a portion of the proceeds of that sale will fund the development of RVX's apabetalone (BOM2). At that point, the market cap of RVX will grow exponentially. 

The success of BOM2 will benefit both RVX and ZHCLF. Resverlogix's market cap will soar. ZCC will collect 6-12% on its royalty-preferred shares, right off the top, in perpetuity, paying out dividends to shareholders.

Koo   (IMO)